/

Società

En

Non verificato

Enodia Therapeutics

Di cosa scriviamo

BiotecnologiaHIV, AIDS e malattie autoimmuniIndustriaOncologiaSalute

3 comunicati stampa

Guarda tutti i comunicati

15/04/2026

Enodia Therapeutics Appoints Dr. Yvonne McGrath as Chief Scientific Officer to Accelerate Upstream Targeted Protein Degradation Platform

Fonte

Enodia Therapeutics

Emittente

1.00

0

08/01/2026

Biotecnologia

Farmaceutica

Oncologia

Salute

HIV, AIDS e malattie autoimmuni

Tecnica

Enodia Therapeutics Secures €20.7M to Advance a Small-Molecule Platform for Targeted Protein Degradation Enabled by Proteomics and Machine Learning

Fonte

Enodia Therapeutics

Emittente

1.00

0

26/02/2025

Multimedialità

Scienza

HIV, AIDS e malattie autoimmuni

Medicina - Varie

Biotecnologia

Salute

Sanità

Oncologia

Industria

Argobio and the Institut Pasteur Launch Enodia Therapeutics: A Biotech Company With a New Approach for Targeted Protein Degradation

Fonte

Enodia Therapeutics

Emittente

1.00

0

Seguaci

0

Compatibilità

0